| Literature DB >> 31673228 |
Hollie Speer1,2,3, Nathan M D'Cunha2,3, Michal Botek3,4, Andrew J McKune2,3,5, Domenico Sergi3,6, Ekavi Georgousopoulou3,7,8, Duane D Mellor3,9, Nenad Naumovski2,3.
Abstract
The prevalence of cardiovascular disease (CVD) is rising worldwide, remaining the major cause of death in developed countries. Polyphenols have been shown to have cardioprotective properties; however, their impact on iron bioavailability and potential impact on other aspects of health is unclear. A systematic review was undertaken to evaluate the current status of the relationship between habitual polyphenol consumption, iron status, and circulating biomarkers of CVD. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2009 guidelines, searches were performed across 5 electronic databases (PubMed, Cochrane Library, Scopus, Web of Science, and CINAHL) to identify randomized controlled trials which investigated the effects of polyphenol consumption on inflammatory markers, serum lipid profile, and iron absorption and bioavailability. In total, 1174 records were identified, with only 7 studies meeting the inclusion criteria. The selected studies involved 133 participants and used a variety of foods and supplements, including olive oil and cherries, rich in polyphenols including hydroxytyrosol, quercetin, and resveratrol, as well as catechin enriched drinks. The duration of the studies ranged from between 56 and 145 days, with total polyphenolic content of the food items and supplements ranging from 45 to 1015 mg (per 100 g). Polyphenols did not appear to interfere with iron status, and most studies reported improvements in inflammatory markers and lipid profile. While these results are promising, the limited number of studies and considerable heterogeneity across the interventions support the need for more extensive trials assessing the relationship between polyphenol intake, iron bioavailability, and CVD risk.Entities:
Keywords: CVD; Polyphenol; atherosclerosis; iron status
Year: 2019 PMID: 31673228 PMCID: PMC6804354 DOI: 10.1177/1178638819882739
Source DB: PubMed Journal: Nutr Metab Insights ISSN: 1178-6388
Figure 1.PRISMA flow chart summary of systematic review search process.
Summary of findings of the included studies.
| Reference | Aims | Study design | Participants (n) | Age (range) mean ± SD | Duration | Polyphenol composition (mg/100 g) | Dose | Outcomes |
|---|---|---|---|---|---|---|---|---|
| Kelley et al[ | Assess the effect of sweet bing cherries on plasma lipids and markers of inflammation | Human clinical trial | Healthy M (n = 2) and F (n = 16) | 50 ± 1 | 64d | Total 135; | 280 g/d | IG: Decrease in CRP ( |
| Kelley et al[ | Examine the effects of cherry consumption on risk factors for multiple chronic diseases in plasma samples from humans with modestly elevated CRP, using a proteomic approach | Human clinical trial | Healthy M (n = 2) and F (n = 16) | All 50 ± 1 | 64d | Total 135; | 280 g/d | IG: No change in plasma concentrations of ferritin, CRP, IL-18. No change in TNF-α ( |
| Lopez-Huertas and Fonolla[ | Assess the effects of HT supplementation on markers of CVD risk and several clinical conditions | Human clinical trial | Healthy M (n = 11) and F (n = 3) | 34.1±[ | 56d | HT; composition not stated in original manuscript | 45 mg/d | Decrease in ferritin ( |
| Soriano-Maldonado et al[ | Investigate the effects of consumption of 2 cloudy apple juices with different polyphenol and VC content on antioxidant status, cardiometabolic and inflammatory markers | Human randomized cross-over study | Healthy M (n = 8) and F (= 12) | 23.7 ± 2.3 | 77d; | VC-rich juice: catechin 510; | 500 mL/d | No difference in blood |
| Suliburska et al[ | To examine the effects of GTE on the mineral, body mass, lipid profile, glucose, and antioxidant status of obese patients | Human prospective, randomized, double-blind control trial | Obese (BMI ⩾ 30 kg/m2) M (n = 23) and F (n = 23) | 50.4 ± 8.3 | 84d | GTE 379; EGCG 208 | 379 mg/d | IG: Decrease in TC ( |
| Urbaniak et al[ | Analyze the effect of POM supplementation on selected pro-inflammatory cytokines, hepcidin, and markers of iron metabolism in well-trained rowers | Human double-blind, placebo-controlled trial | Healthy M (n = 19) | 20.8 ± 0.8 | 61d | Total 220; | 50 mL/d | IG: No effect on serum hepcidin, myoglobin, or creatine kinase levels (all |
| Villaño et al[ | Investigate a citrus-based juice, rich in polyphenols and VC, along with long-term exercise on iron status | Human cross-over study | Healthy M (n = 10) and F (n = 6) | (19–21) | 145d | Total 125; | 200 mL/d | IG: No effect on plasma hepcidin concentration in either groups and no significant difference observed in iron absorption between IG and PG (all |
Abbreviations: BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; d, day; EGCG, epigallocatechin gallate; F, female; FRAP, ferric reducing antioxidant power; GTE, green tea extract; HDL-C, high-density lipoprotein cholesterol; HFA, hydroxy fatty acids; HT, hydroxytyrosol; IG, intervention group; IL-6, interleukin 6; LDL-C, low-density lipoprotein cholesterol; M, male; NO, nitric oxide; ox-LDL, oxidized low-density lipoprotein; PG, placebo group; POM, pomegranate juice; TC, total cholesterol; TG, triglycerides; TNF-α, tumor necrosis factor-alpha; VC, Vitamin C; VLDL-C, very-low-density lipoprotein cholesterol.
SD not reported in original manuscript.
Risk of bias of the included studies.
| Bias category | Kelley et al[ | Kelley et al[ | Lopez-Huertas and Fonolla[ | Soriano-Maldonado et al[ | Suliburska et al[ | Urbaniak et al[ | Villaño et al[ |
|---|---|---|---|---|---|---|---|
| Random sequence generation (selection bias) | Low | Low | Low | Low | Low | Low | Low |
| Allocation concealment (selection bias) | Low | Low | Low | Low | Low | Low | Low |
| Blinding of participants and personnel (performance bias) | Low | Low | Low | Low | Low | Low | Low |
| Incomplete outcome data (attrition bias) | Low | Low/unclear | Low | Low | Low | Low | Low |
| Blinding outcome assessment (detection bias) | Low | Low | Low | Low | Low | Low | Low |
| Selective reporting | Low/unclear | Low | Low | Low | Low | Low/Unclear | Low |
| Other bias | Low | Low | Low | Low | Low | Low | Low |
| Country | The United States | The United States | Spain | Spain | Poland | Poland | Spain |
| Source of funding | Unclear | Unclear | Government/Institution | Government/Institution | Unclear | Government | Institution |